Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Curis Inc (NASDAQ:CRIS)

1.70
Delayed Data
As of May 27
 -0.01 / -0.58%
Today’s Change
1.25
Today|||52-Week Range
3.75
-41.58%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$219.6M

Company Description

Curis, Inc. is a biotechnology company, which is focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Its pipeline includes is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase, or HDAC, and phosphatidylinositol-3-kinase, or PI3K enzymes. The company conducts research programs both internally and through strategic collaborations. Curis was founded on February 14, 2000 and is headquartered in Lexington, MA.

Contact Information

Curis, Inc.
4 Maguire Road
Lexington Massachusetts 02421
P:(617) 503-6500
Investor Relations:
(617) 503-6605

Employees

Shareholders

Other institutional30.92%
Mutual fund holders24.54%
Individual stakeholders19.88%

Top Executives

Ali FattaeyPresident, Chief Executive Officer & Director
James E. DentzerChief Financial Officer, Secretary & Treasurer
Mark W. NoelVP-Technology Management & Intellectual Property
Lisa MassmanianDirector-Clinical Operations
David TuckChief Medical Officer & Senior Vice President